PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma
Status: Recruiting
Location: See location...
Intervention Type: Behavioral, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This study aims to refine and pilot test PDAC-PATHWAYS, a digital informational and supportive care app for patients who are initiating neoadjuvant therapy for pancreatic ductal adenocarcinoma (PDAC).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age≥18 years
• Within 8 weeks of a documented decision to pursue neoadjuvant therapy for newly diagnosed, non-metastatic PDAC
• Able to comprehend and speak English
Locations
United States
Massachusetts
Massachusetts General Hospital
RECRUITING
Boston
Contact Information
Primary
Kelsey Lau-Min, MD, MSCE
klau-min@mgh.harvard.edu
617-724-4000
Time Frame
Start Date: 2025-10-06
Estimated Completion Date: 2027-08
Participants
Target number of participants: 50
Treatments
Experimental: PDAC-PATHWAYS
PDAC-PATHWAYS is an informational and supportive care app for patients initiating neoadjuvant therapy for PDAC.
Active_comparator: Usual care
Participants randomized to usual care will receive routine treatment with their oncology clinicians.
Related Therapeutic Areas
Sponsors
Collaborators: United States Department of Defense
Leads: Massachusetts General Hospital